Free radical scavengers or antioxidants (A61P39/06)

A   Human necessities(312083)
A61P39        General protective or antinoxious agents(420)
A61P39/06                     Free radical scavengers or antioxidants(219)

Flavonoid-based composition for pharmaceutical, dietary or cosmetic application with enhanced antioxidant action // 2640915
FIELD: pharmacology.SUBSTANCE: pharmaceutical composition possessing antioxidant activity against free radicals, containing: a) extract of seeds or seeds and leaves of Vitis vinifera, including a combination of quercetin and catechin flavonoids content at a molar ratio in the range from 6:1 to 3:1, or a') extract of seeds or seeds and leaves of Vitis vinifera, including a combination of quercetin and catechin flavonoids content at a molar ratio in the range from 7:1 to 4:1, or a") blend of Vitis vinifera extracts of a) and a'), or a'") a mixture of catechin and quercetin at a molar ratio in the range from 7:1 to 3:1, along with b) Olea europaea L. olive leaves extract containing hydroxytyrosol in an amount ranging from 1% to 30% of the extract mass, or b') hydroxytyrosol in an amount equal to the one contained in the extract (b), wherein the a'), or a"), or a"') and b), or b') ration is in the range between 6:1 to 6:3. Cosmetic application of the composition to provide antioxidant activity against free radicals. Composition application as a food dietary supplement to provide antioxidant activity against free radicals.EFFECT: compositions described above have a pronounced synergistic antioxidant activity.22 cl, 2 dwg, 8 ex
ethod for prevention of neurological status and muscular tonus violations in acute radiation disease in experiment // 2638270
FIELD: medicine.SUBSTANCE: to prevent psychoneurological disturbances in an animal experiment after single uneven proton irradiation at doses capable of causing acute radiation disease, Semax preparation 0.1% nasal drops is administered intranasally. Semax is injected 1 drop into each nostril three times a day from 1 to 7 days after exposure to radiation.EFFECT: method allows to maintain a normal level of the orienting-research reaction, emotional status, the relationship between the excitation and inhibition processes of the central nervous system and muscle tone, disturbed by proton irradiation.2 ex, 1 tbl

Pharmaceutical possessing hypolidemic, hepatoprotective and antioxidant action // 2636817
FIELD: pharmacology.SUBSTANCE: pharmaceutical contains a powder of medicinal and food plants, as well as calcium gluconate and camphor with a certain ratio of components. This agent can be used both in the form of a powder and in the form of capsules. Pharmaceutical and capsules based on it can be used in the treatment and prevention of atherosclerosis, coronary heart disease (CHD), hyperpiesis, diabetes, obesity, varying degrees of lipid and carbohydrate metabolism, as well as in geriatric practice.EFFECT: increased efficiency of the pharmaceutical use.16 tbl, 1 dwg, 2 ex
Complex connection of 5-hydroxy-3,6-dimethyluracyl with succinic acid exhibiting membrane-stabilizing activity and method of its production // 2631238
FIELD: chemistry.SUBSTANCE: complex compound is produced by mixing equimolar amounts of 5-hydroxy-3,6-dimethyluracil with succinic acid in an organic solvent, followed by heating the reaction mixture for 1 hour at 70°C, cooling the reaction mixture and filtering the precipitated crystals. .EFFECT: having membrane-stabilizing and anti-radical activity, reduced toxicity in comparison with the known compounds of identical purpose.2 cl, 3 tbl, 4 ex
Composition with antioxidant activity and its application // 2630579
FIELD: pharmacology.SUBSTANCE: composition with antioxidant activity, containing a gel from aloe vera leaves; grapes juice; green tea extract; vitamin mixture containing vitamin B1, vitamin B9, vitamin B12 and vitamin E; chlorophyll; coenzyme Q10; choline; selenium and a wheat unit extract containing 10% of resveratrol taken in a certain amount.EFFECT: composition provides high antioxidant activity.10 cl, 1 tbl, 3 ex
Pharmaceutical "biobardin" pills with antioxidant action obtained based on post-alcohol grain distillery dreg // 2630466
FIELD: pharmacology.SUBSTANCE: invention relates to a method for preparation of an antioxidant drug in the form of pills based on biologically active compounds (BAC) of post-alcohol grain distilled dreg. First, effective antioxidant drug (pharmaceutical substance) "Biobaridin" is obtained from liquid and solid phases of post-alcohol grain distilled dreg by a known mehod (Pat. RF No. 2404766) in a powder form. The substance is then ground, powder fraction passed through a sieve with a hole diameter of 1.0 mm (sieve No. 10) and not passed through a sieve with a hole diameter of 0.5 mm (sieve No. 05) is selected, i.e. coarse powder with a particle size of 0.5-1.0 mm is selected. The selected substance fraction is mixed for 5 minutes with calcium hydrogen phosphate (filler), granulated with 10% alcohol solution of collidon-25 (binder), dried in a fluidized bed at a temperature of 40°C for 30 minutes (up to the residual granulate moisture content of 2.8%), dry granulate is passed through a sieve with a hole diameter of 1.5 mm (sieve No. 15), "powdered" with calcium stearate (lubricant) and pressed into "Biobardin" pills. The composition of one "Biobardin" pill weighing 0.21 g: "Biobardin" substance 0.16 g, calcium hydrophosphate 0.04 g, collidon-25 0.009 g (or 0.09 g of 10% collidon-25 alcohol solution), calcium stearate 0.001 g.EFFECT: development of the composition and technology of antioxidant pills based on biologically active compounds isolated from distilled dreg, possessing optimal parameters for pharmaceutical use, long shelf life.2 cl, 1 ex, 11 tbl
Polybacterial drug with advantages for health: with antioxidant effect, decreased cholesterol concentration, anti-inflammatory and immuno-modulating effect, and release of bioactive peptides inhibiting angiotensin-converting enzyme // 2627651
FIELD: biotechnology.SUBSTANCE: group of inventions refers to polybacterial probiotic drug including new strains of lactic acid bacteria Lactobacillus gasseri 7/12 NBIMCC No. 8720, Lactobacillus plantarum F12 NBIMCC No. 8722 and Lactobacillus helveticus A1, NBIMCC No. 8721, which has anti-inflammatory immunomodulatory, hypocholesterolemic, antioxidant and antihypertensive activity. The group of inventions also refers to the use of drug as a probiotic agent, as well as an agent which has anti-inflammatory immunomodulatory, hypocholesterolemic, antioxidant and antihypertensive activity.EFFECT: food additives, food and functional products, pharmaceutical preparations that include this drug, have a beneficial effect on the health of people and animals.9 cl, 8 dwg, 15 tbl
2-[6-methyl-4-(tietane-3-yloxy)pyrimidine-2-ylthio] acetic acid methylidenhydrazide with antioxidant activity // 2626651
FIELD: pharmacology.SUBSTANCE: invention relates to a new compound of -(5-bromo-2-hydroxyphenyl)methylidenehydrazide of 2-[6-methyl-4-(thietane-3-yloxy)pyrimidin-2-ylthio]acetic acid of formula I .EFFECT: compound has antioxidant activity and stimulating protective activity of phagocytes.3 cl, 4 tbl, 4 ex
Therapeutic application of krill oil // 2625760
FIELD: medicine.SUBSTANCE: proposed: method for endotoxemia treatment by parenteral administration of a krill oil composition containing phospholipids derived from krill, in an oil-in-water emulsion for injection, wherein triglycerides comprise at least 60% of omega-3 fatty acids based on the total weight of fish oil triglyceride fatty acids; application of the said composition for the same purpose; method for high-lipophilic drugs excessive doses toxicity neutralisation or drugs harmful effects reduction, comprising parenteral administering of the said composition; use of krill oil containing phospholipids derived from krill as an emulsifier in an oil-in-water emulsion in the composition for injection, and its use for endotoxemia treatment during sepsis.EFFECT: stability and safety of claimed compositions for intravenous administration.5 cl, 9 tbl
Pharmaceutical injection form of hydrophilic conjugate of hydroxyethylamylum and 2,6-diisobornyl-4-methylphenol, method for its production and applications for cardiovascular diseases treatment // 2625039
FIELD: pharmacology.SUBSTANCE: pharmaceutical injection form of hydrophilic conjugate of hydroxyethylamylum and 2,6-diisobornyl-4-methylphenol for cardiovascular diseases treatment contains a therapeutically effective amount of O-(4-hydroxy-3,5-di(1,7,7-trimethylbicyclo[2.2.1]hept-exo-2-yl)benzyl)oxy)ethyl)-O-(2-hydroxyethyl)-(1,4)-α-D-glucan (Dibornol-HEC) as an active ingredient. Sodium chloride, Tween 80, ascorbic acid, water for injection or saline in the amounts indicated in the claims are used as auxiliary components. In the method for pharmaceutical injection form preparation, the Dibornol-HEC substance is added to an aqueous solution of Tween 80 surfactant and mixed until the substance is dissolved completely and a clear solution is obtained, the water is distilled off under reduced pressure, ascorbic acid, sodium chloride, saline (water for injection) are added to the dry residue and mixed, the solution is adjusted to a concentration of 4.5-7.5% by the active Dibornol-HEC substance with saline (water for injection) and centrifuged, if necessary, the solution is filtered, the resulting drug solution is poured into glass vials or ampoules, which are sealed and packaged.EFFECT: pharmaceutical injection form of the invention is stable.2 cl, 1 tbl, 15 ex
Device for water hydrogenation // 2620802
FIELD: chemistry.SUBSTANCE: device for water hydrogenation contains a hydrogen generator 3, a tank 4 for the preparation of hydrogen water, a line for water supply and diversion of water to the consumer, shut-off and regulating armature. The container 4 for the preparation of hydrogenated water contains a hydrogenation catalyst and is connected through a non-return valve to the hydrogen generation unit. The hydrogen generation unit consists of a hydrogen generator 3 connected 6 to the means of maintaining hydrogen pressure and shutting off the hydrogen generator 3 when the hydrogen pressure is exceeded, and the tank 2 with desalted water. The tank 2 with desalted water is connected to the hydrogen generator 3 by a line for supplying desalted water and hydrogen supply to it.EFFECT: invention allows to remove all oxidants from water, ensure saturation of water with hydrogen and create in it a negative oxidation-reduction potential in the absence of the possibility of creating in the water genotoxic activity.2 cl, 2 dwg
ethod for oxidative stress correction under conditions of ultraviolet irradiation // 2619875
FIELD: medicine.SUBSTANCE: laboratory rats receive daily oral administration of the herb infusion of corn grassworm at a rate of 5 ml/kg of mass 20 minutes before exposure to ultraviolet rays, under ultraviolet irradiation conditions. The infusion is obtained by infusion of 5 g of herbs for 200 ml of boiling water for 60 minutes.EFFECT: method provides oxidative stress correction based on reduced content of lipid peroxidation products in irradiated rats and increased activity of antioxidant system with a shortened phytocorrection course.3 tbl
ethod for preparing agent having stressprotective and antioxidant activity // 2619856
FIELD: pharmacology.SUBSTANCE: cornflower saw-wort grass, crushed to the size of 1.0-2.0 mm, is extracted three times at 60°C at the ratio of raw materials in pts. wt. and the extractant in pts.vol. 1:12. The first phase contact - 70%-ethyl alcohol for 90 minutes, the second phase contact - 40%-ethyl alcohol for 60 minutes and the third phase contact - 20%-ethyl alcohol for 60 minutes. The combined aqueous alcohol extracts are filtered, evaporated, purified by separation, residual evaporated, then dried in a vacuum drying apparatus.EFFECT: method allows to expand the range of herbal medicines with stressprotective and antioxidant activity.15 tbl, 1 ex

edication for prevention and treatment of free radical pathology in animals // 2619342
FIELD: veterinary medicine.SUBSTANCE: medication for the prevention and treatment of Pathology findings in animals contains 3.0-5.0 mas.% of phenyl-tert-butilnitrona, 1.0-2.0 mas.% β-carotene, 7.5-10.5 mas.% 2.6-ditretbutil-4-nonylphenol, 10.0-15.0 mas.% of 2,4,6,8-tetramethyl-2,4,6,8-tetraazabicyclo-(3,3,0)-oktadyselenon-3.7, 5.0-9.0 mas.% Solutol HS15, 0.2-0.4 mas.% Polyvinylpyrrolidone and water for injection (the rest).EFFECT: increasing the stress resistance of the organism, reducing toxicity and increased ease of use and dosage.dwg 6 7 ex
ethod for organism adaptability increasing under uv exposure // 2616504
FIELD: medicine.SUBSTANCE: drug is administered to laboratory animals daily, 20 minutes before exposure to ultraviolet rays. At that, rats receive 500 mg/kg of arabinogalactan intramuscularly for 6 days, as a drug.EFFECT: increased adaptation capabilities of organism in terms of ultraviolet radiation, based on the reduction of radical products and lipid peroxides content in bodies of irradiated rats and increase of antioxidant activity, under the conditions of reduced duration of the correction course (to 6 days) compared to the prototype.3 tbl
ixture of medicinal plants with antioxidant activity // 2613171
FIELD: medicine, pharmaceutics.SUBSTANCE: invention relates to pharmaceutical industry, namely to mixture of medicinal plants with antioxidant activity. Mixture of medicinal plants with antioxidant activity includes shoots of Atragene sibirica, green leaves of Bergenia crassifolia and herb of meadowsweet, in specified ratio of components.EFFECT: mixture possesses increased antioxidant action.1 tbl, 5 ex
ethod of increasing radioresistance in small cattle, subjected to ionizing radiation // 2613102
FIELD: medicine; veterinary science; physics.SUBSTANCE: invention relates to radiation biology and radiation medicine and is intended for prevention and treating acute radiation disease caused by ionizing radiation. Method involves using preparation curcumine in amount of 3.125–3.47 mg of pure substance of curcumine per 1 kg of live weight, injected intramuscularly in dose of 10.0 cm3 0.5–1.0 h after irradiation, if absorbed dose is 4.0–5.0 Gy, and intramuscularly in dose of 10.0 cm3 0.5–1.0 h after irradiation and additionally in dose of 10.0 cm3 on 3 and 5 days after irradiation, if absorbed dose is 5.0–6.0 Gy.EFFECT: method is highly effective for increasing radioresistance in small cattle, subjected to ionizing radiation.1 cl, 2 tbl, 1 ex

Agent increasing expression of redox factors // 2606856
FIELD: medicine.SUBSTANCE: present invention provides maintenance of homeostasis of organisms and concerns: agent for reducing expression IL-1β in the skin of object and for increasing of expression of redox associated factor in human epidermal cell. Agent can include kaempferol, where redox factor is selected from group, consisting of one or more of the number of thioredoxin, thioredoxin reductase, glutathione reductase and glutaredoxin. Agent can include extract of ginkgo leaves, obtained by dissolving 50 % ethanol extract of Ginkgo biloba L. leaves in 1,3-butyleneglycol, where redox-associated factor is thioredoxin and/or thioredoxin reductase. Agent can include extract of galanga Kaempferia galanga, prepared by extraction with 50 % 1,3-butyleneglycol, where redox-associated factor is selected from group consisting of one or more of the number of thioredoxin, thioredoxin reductase, glutathione reductase and glutaredoxin.EFFECT: maintenance of homeostasis of organisms.16 cl, 6 ex, 6 dwg

Novel compound with effects of thrombolysis, accepting free radicals and directed action on thrombus, as well as method for production and use thereof // 2604193
FIELD: chemistry.SUBSTANCE: invention relates to a novel compound of formula I-1, characterised by effects of thrombolysis, accepting free radicals and directed action on thrombus. Compound is a three-component conjugate formed by conjugation of thrombolytic oligopeptide, free radical acceptor and a peptide with directed action on thromb/antithrombotic oligopeptide by binder link.EFFECT: present invention also relates to a pharmaceutical composition containing compounds, wherein compounds form a nanospherical structure.13 cl, 40 dwg, 21 tbl, 17 ex

ethod for producing agent possessing anti-ischemic and antioxidant activity // 2603465
FIELD: pharmaceutics.SUBSTANCE: invention relates to pharmaceutical industry, particularly to a method for producing the agent, possessing anti-ischemic and antioxidant activity. Disclosed is a method for producing agent possessing anti-ischemic and antioxidant activity, by grinding plant repertory, comprising Membranous Milk Vetch roots, Baikal skullcap roots, Siberian Alexandrian laurel rhizomes and roots, by its three-stage extraction with 60 % ethanol, then, banded aqueous-alcoholic extracts are being filtered, evaporated, purified by separation, finally boiled out, then dried in a vacuum drying apparatus under certain conditions.EFFECT: agent produced as described above possesses the evident anti-ischemic and antioxidant activity.1 cl, 10 tbl

ethod of producing water-soluble lyophilisate of 4-(3-oxo-3-ethoxypropanoyl)amino)benzoic acid possessing anti-ischemic and antioxidant activity // 2602665
FIELD: pharmaceutics.SUBSTANCE: invention relates to chemical-pharmaceutical industry and represents a method of producing a water-soluble lyophilisate, involving producing a combined solution of an active substance and a compound containing hydroxyl and amino groups (amino alcohol), characterized by that the active substance is 4-((3-oxo-3-ethoxypropanoyl)amino)benzoic acid (EPABA) possessing anti-ischemic and antioxidant activity. Amino alcohol is selected from a group of N-methylglucamine or tris(hydroxymethyl)aminomethane; herewith the said substance and amino alcohol taken in the molar ratio from 1:1 to 1:10 are dissolved in water, the solution is added with an acid agent up to pH 6.8-7.5, neutral solution is filtered, frozen and dried by sublimation.EFFECT: invention enables to obtain water-soluble stable neutral lyophilisates of EPABA corresponding to process requirements of preparations for parenteral administration.3 cl, 4 dwg, 4 tbl, 2 ex
Agent possessing general strengthening and antioxidant action // 2601624
FIELD: pharmaceutics.SUBSTANCE: invention refers to pharmaceutical industry, namely to an agent possessing general tonic, antioxidant action. Agent contains apple pectin, source of biologically active substances (BAS), glutathione, amino acids, potassium sorbate, water with negative oxidation-reduction potential from -200 to -240 mV, taken in a certain amount. BAS source is selected from: extract of red wine, and/or extract of hawthorn fruits, and/or cranberry fruit extract, and/or rosehips extract with vitamin C, and/or extract of spinach, and/or extract of stems and pineapple fruits, and/or celery extract, and/or red bilberry extract, and/or extract of juniper, and/or melon extract, and/or orange extract, and/or oat extract, and/or extract of black currants, and/or sprouts extract broccoli, and/or ginger root extract, and/or mango extract, and/or walnut extract, and/or extract of berries, and/or extract of green tea, and/or Bilberry fruit extract, and/or raspberry extract and/or quercetin, and/or soya isoflavones. Amino acid selected from: alanine, and/or aspartic acid, and/or glutamine, and/or glutamic acid, and/or arginine, and/or leucine, and/or lysine, and/or proline.EFFECT: agent described above possesses the pronounced general tonic, antioxidant action, increased storage life.4 cl, 9 ex

Agent having antioxidant, anti-tumor, immunomodulatory, anti-diabetic and anti-bacterial action // 2598349
FIELD: medicine.SUBSTANCE: proposed agent having antioxidant, anti-tumor, immunomodulatory, anti-diabetic and anti-bacterial action, relates to medicine. It comprises an aqueous extract from plant material. As a raw material use peach and birch leaves. In addition, agent contains ascorbic acid and the trivalent chromium microelement in the amounts indicated in the invention formula.EFFECT: agent of the invention expands the range of drugs, has no adverse side effects and can be recommended for long-term continuous use.1 cl, 1 dwg, 4 tbl

Antioxidant composition (versions) // 2593587
FIELD: pharmaceutics. SUBSTANCE: invention relates to pharmaceutical industry and represents use of antibacterial and antiviral pharmaceutical composition, having pronounced anticancer, antibacterial and antioxidant properties, containing silver nitrate, hexamethylenetetramine, sodium thiosulphate, alpha-aspartic acid or asparagine, nicotinic acid and water, wherein ingredients of composition are taken in a certain ratio, wt%, and also represents use of antibacterial and antiviral pharmaceutical composition, having pronounced anticancer, antibacterial and antioxidant properties, containing silver nitrate, hexamethylenetetramine or imidazole, alpha-aspartic acid or asparagine, nicotinic acid, imidazole-containing compounds of platinum cis-[Pt (NH3)2Im2]Cl2 or CIS-[Pt (NH2OH)2Im2]Cl2 and water, wherein ingredients of composition are taken in certain ratio, wt%. EFFECT: invention widens range of agents for said purpose, wherein claimed composition can be used as an integral part or as independent preparation, having therapeutic and preventive properties, preventing damage to cells by free radicals, improving body defences and promoting tissue regeneration. 2 cl, 2 ex, 1 tbl

Antioxidant composition // 2593010
FIELD: medicine; pharmaceuticals. SUBSTANCE: invention relates to chemical-pharmaceutical industry and represents an antioxidant composition containing lithium aspartate in amount of 40-60 wt% and lithium succinate in amount of 40-60 wt%. Disclosed composition allows for long-term storage and retains activity at room temperature for six months. EFFECT: invention provides a wider range of antioxidant agents. 1 cl, 1 tbl, 3 ex

ethod for prevention of stress in chickens for meat production at beak trimming // 2588542
FIELD: veterinary science.SUBSTANCE: invention relates to a method for prevention of stress in chickens for meat productivity during beak trimming. Method involves using pharmacological agents possessing antistress action. Chickens from birth and up to 7-10-days of age take water with a daily dose of 280-320 mg/kg of body weight of a pharmacological complex containing following components, wt%: betaine 30-35; ascorbic acid 10-15; succinic acid 10-15; L-carnitine tartrate 15-20; butaphosphane 8-10; glucose - balance. Additionally 2-3 days prior to beak trimming, on beak trimming day and 2-3 days after beak trimming in a dose of 230-250 mg/kg of body weight is used pharmacological complex including, wt%: lithium citrate 8-10; ascorbic acid 10-15; succinic acid 10-15; butaphosphane 30-35; L-carnitine tartrate 15-20; glucose - balance, and 2-3 days prior to beak trimming, on beak trimming day and 1-2 days after beak trimming daily fodder is taken with vitamin K in a dose of 50-100 mg per chicken.EFFECT: invention allows effective prevention of stress, reduces chicken waste, increases average daily weight gain.1 cl, 8 tbl

ethod for preparation of liquid antioxidant // 2587541
FIELD: chemistry.SUBSTANCE: invention relates to method of liquid antioxidant preparing. Method consists in fact that in fresh water in vessel in equilibrium with environment, potato starch is filled at a weight ratio of starch to water of 1:(50-100), then liquid is mixed and left in vessel for 16-24 hours, during this period contents of vessel is stirred 4-8 times. Before filling in starch, water is boiled and cooled to room temperature.EFFECT: ease of producing liquid antioxidant and low price of its main component, potato starch.1 cl, 2 dwg

Bis- (3- (3,5-di-tert-butyl-4-hydroxyphenyl) propyl) selenide, having antioxidant and hypoglycemic activity // 2586067
FIELD: chemistry.SUBSTANCE: invention relates to selenium-containing phenol compound - bis-(3-(3,5-di-tert-butyl-4-hydroxyphenyl)propyl)selenide with formula: .EFFECT: disclosed compound exhibits high antioxidant activity, low toxicity and hypoglycaemic action with underlying diabetes, and can be used in medicine, veterinary and experimental biology.1 cl, 1 dwg, 3 tbl, 5 ex

Agent with liposomes containing nicotinic acid and propolis extract having detoxification and antioxidant activity // 2585099
FIELD: chemistry.SUBSTANCE: invention relates to an agent possessing detoxification and antioxidant activity. Agent contains nicotinic acid and 10% alcohol extract of propolis, included in liposomes. Said liposomes are obtained by mixing at 40°C egg lecithin and cholesterol, taken in ratio 1:0.2, followed by hydrating with solution of sucrose. Liposomes are enclosed in capsules for oral administration in following ratio of components of liposomes per 1 capsule: 0.2 g nicotinic acid, 0.2 g of 10 % alcohol extract of propolis, 0.22 g of mixture of lecithin and cholesterol 1:0.2, hydrated with 0.5 % sucrose solution.EFFECT: invention is characterised by high bioavailability and marked prolonged action, providing maximum delivery of active substances of gastrointestinal tract in blood flow.3 cl, 5 tbl, 7 ex

Agents with anti-inflammatory and antioxidant activity // 2578473
FIELD: medicine.SUBSTANCE: invention relates to an agent having anti-inflammatory and antioxidant activity. Said agent is a complex of inclusion of 6-[(difluorbutilamino) methyl]-dihydroquercetin into cyclodextrin.EFFECT: invention provides a reduction in the inflammatory response.1 cl, 1 dwg, 1 tbl

Probiotic bacteria having antioxidant activity and use thereof // 2572698
FIELD: medicine.SUBSTANCE: group of inventions refers to medicine and concerns treating oxidative stress with using at least one bacterial strain possessing antioxidant properties, specified in Bifidobacterium lactis BS 05 (ID 1666) deposited in Probiotical SpA, Novara (Italy) in German collection of microorganisms and cell cultures (DSMZ) in Germany 13.10.2009 under deposition number DSM 23032; Lactobacillus acidophilus LA 06 (ID 1683) deposited in Probiotical SpA, Novara (Italy) in DSMZ in Germany 13.10.2009 under deposition number DSM 23033; and Lactobacillus brevis LBR01 (ID 1685) deposited in Probiotical SpA, Novara (Italy) in DSMZ in Germany 13.10.2009 under deposition number DSM 23034. The group of inventions also concerns a composition used in treating oxidative stress, containing at least one bacterial strain described above.EFFECT: group of inventions provides treating oxidative stress.17 cl, 8 ex, 2 dwg, 4 tbl

ethod for light-emitting diode phototherapy in chronic nasal polyposis // 2570543
FIELD: medicine.SUBSTANCE: preliminary interstitial laser-induced heat treatment with high-energy laser beam covering nasal polyp tissue is followed by introducing 1% emoxipine in an amount up to 1.0 ml into a polyp stroma. A distal end of a flexible light pipe of AFS/IK light-emitting-diode therapy apparatus emitting infrared light is brought to the polyp. A light power is 60 mW/cm2; a spot diameter is up to 2 cm. The polyp is illuminated for 5 minutes daily for 7 days.EFFECT: method enables accelerating the process of nasal polyp tissue shrinking and necrotising tissue rejection that is ensured by fast accumulation of an antioxidant in the polyp stroma induced by the phototherapy, lipid peroxidation suppression, and improved antioxidant tissue protection.2 tbl, 1 ex

ethod for phototherapy in chronic polypous rhinosinusitis // 2570532
FIELD: medicine.SUBSTANCE: preliminary interstitial laser-induced heat treatment with high-energy laser beam covering nasal polyp tissue is followed by introducing 1% emoxipine in an amount up to 1.0 ml into a polyp stroma. A distal end of a flexible light pipe of AFS/K light-emitting-diode therapy apparatus emitting visible red light is brought to the polyp. A light power is 60 mW/cm2; a spot diameter is up to 2 cm. The polyp is illuminated for 5 minutes daily for 7 days.EFFECT: method enables accelerating the process of nasal polyp tissue shrinking and necrotising tissue rejection that is ensured by fast accumulation of an antioxidant in the polyp stroma induced by the phototherapy, lipid peroxidation suppression, and improved antioxidant tissue protection.2 tbl, 1 ex

ethod for light-emitting diode phototherapy in chronic nasal polyposis // 2570530
FIELD: medicine.SUBSTANCE: preliminary interstitial laser-induced heat treatment with high-energy laser beam covering nasal polyp tissue is followed by introducing 1% emoxipine in an amount up to 1.0 ml into a polyp stroma. A distal end of a flexible light pipe of AFS/Z light-emitting-diode therapy apparatus emitting visible green light is brought to the polyp. A light power is 60 mW/cm2; a spot diameter is up to 2 cm. The polyp is illuminated for 5 minutes daily for 7 days.EFFECT: method enables accelerating the process of nasal polyp tissue shrinking and necrotising tissue rejection that is ensured by fast accumulation of an antioxidant in the polyp stroma induced by the phototherapy, lipid peroxidation suppression, and improved antioxidant tissue protection.2 tbl, 1 ex

ethod for producing therapeutic agent possessing antioxidant activity // 2568908
FIELD: medicine.SUBSTANCE: herbal material is ground, extracted three times by alcohol water mixture; extracts are combined, concentrated under vacuum; the extract is cleaned by centrifugation, dried and ground in the certain environment. The total content of phenol compounds in the prepared agent in terms of the equivalent amount of rutin makes not less than 5%, whereas the resveratrol content makes not less than 0.005%.EFFECT: high antioxidant activity of the therapeutic agent.2 cl, 2 tbl

ethod of phototherapy with antioxidant in case of chronic polypoid rhinosinusitis // 2566436
FIELD: medicine.SUBSTANCE: laser interstitial thermotherapy of a polipoid tissue in the nasal cavity is preliminarily performed with high-energy laser radiation. A day after the said procedure a 1% solution of emoxipine in a volume up to 1.0 ml is introduced into the polyp stroma. After that, the distal end of a flexible light guide of the light diode therapy apparatus "AFS/S", radiating visible blue radiation with a wavelength of 0.45 mcm, power of radiation of 120 mW, light spot diameter up to 2 cm, is brought to the polyp. After that, the 5-minute long illumination of the polyp is carried out, with the repetition of the entire course daily, for 7 days.EFFECT: amplification of the emoxipine solution effect on the polypoid tissue of the nose, reduction of recovery terms, and recovery of nasal respiration.2 tbl, 1 ex

ethod for laser phoresis in treating chronic rhinosinusitis polyposa // 2566211
FIELD: medicine.SUBSTANCE: laser interstitial thermal therapy (LITT) with high-energy laser light irradiation of polyp tissue is followed by infiltration administration of 1% emoxypine in an amount of up to 1.0 ml into a polyp stroma. A distal end of a light guide of a helium neon laser at wave length 0.63 mcm is delivered to the polyp. A maximum output power of the laser light is 40 mW. A power flow density is 35-60 mW/cm2. A light spot diameter is 2 cm. A single radiation dose is from 3.5 to 5.5 J/cm2. The polyp is exposed for 5 minutes daily during 7 days.EFFECT: method enables increasing the therapeutic action of emoxypine solution on the polyp nasal tissue manifested by inhibition of lipid peroxidation processes, increased antioxidant tissue protection, thereby decreasing polyp oedema, its shrinking and rejection of necrotic tissues.2 tbl, 1 ex

ethod of treating ischemic hepatic injuries // 2563796
FIELD: medicine.SUBSTANCE: hepatectomy using an intraoperative extracorporeal temporal portacaval shunt is performed in an experimental animal. On the day of the surgical intervention, the slow intravenous bolus administration of Heptral, the solution for injections, follows 1.5 hours prior to the surgical intervention in a dose of 2 mg/kg, 2 hours after the first administration - in a dose of 6 mg/kg and 8 hours after the first administration - in a dose of 4 mg/kg. What is also required is the slow intravenous bolus administration of Clarithromycin in NaCl solution 0.5 in a dose of 3 mg/kg three times a day at 700, 1500 and 2300. The postoperative period involves administering Heptral two times a day - at 900 in a dose of 7 mg/kg, at 1600 in a dose of 5 mg/kg; Clarithromycin - three times a day at 700, 1500 and 2300 in a dose of 3 mg/kg. The total length of administering Heptral and Clarithromycin is 10 days.EFFECT: method provides treating, correcting and preventing a surgical infection, ischemic and reperfusion hepatic injuries, lengthening safe periods of liver exsanguinations and avoiding major haemorrhages potentially accompanying the hepatic surgical intervention.3 ex, 5 tbl

Eufrazine, medicinal herb tea possessing antioxidant and nootropic activity // 2560077
FIELD: medicine, pharmaceutics.SUBSTANCE: invention refers to chemical-pharmaceutical industry, namely to a medicinal herb tea possessing antioxidant and nootropic activity. The tea contains blueberries, eyebright herb, meadowsweet blossom, lemon balm herb, cinnamon rose taken in certain proportions.EFFECT: tea extends the range of herbal medicinal products possessing antioxidant and nootropic activity, as well as has high pharmacological activity.1 dwg, 4 tbl

Composition for mitigating fatigue, formulation and using them // 2559784
FIELD: medicine, pharmaceutics.SUBSTANCE: group of inventions involves a composition for mitigating fatigue containing 0.5-1 mg/kg of 20(S)-protopanaxadiol and 120-480 mg/kg of Lycium barbarum polysaccharide, a formulation for a specified application, as well as using the composition and the formulation (version) for producing drug preparations and medicinal products for mitigating fatigue.EFFECT: composition or formulation shows a significant effect of mitigating fatigue as compared to one achieved by using Lycium barbarum polysaccharide or 20(S)-protopanaxadiol only.11 cl, 2 tbl, 3 ex

Antioxidant preparation from aboveground part of ramsons (bear's onion or long-rooted onion) // 2559594
FIELD: medicine.SUBSTANCE: medication, possessing antioxidant activity, is characterised by the fact that it is obtained by the purification of a freshly collected aboveground part of bear's onion, collected at the beginning of a vegetation stage, washing, drying, crushing, under specified conditions (versions).EFFECT: medication possesses an expressed antioxidant activity.2 cl, 3 tbl, 6 ex
Antioxidant agent of nanostructured selenium with hepatoprotective effect and methods for producing and using it // 2557992
FIELD: medicine, pharmaceutics.SUBSTANCE: invention refers to pharmaceutical industry, namely to selenium nanocomposites of natural hepatotrophic galactose-containing polysaccharide matrixes, representing water-soluble orange-red powders containing zerovalent selenium (Se0) nanoparticles sized 1-100 nm in the quantitative content of 0.5 - 60 wt %, possessing antioxidant activity for treating and preventing redox-related pathologies, particularly for treating toxic liver damage, to a method for producing and to an antioxidant agent containing the above nanocomposites.EFFECT: invention provides the targeted agent delivery to liver cells, as well as higher agent accessibility and lower toxic action of selenium.7 cl, 11 ex, 4 tbl

Agent for treating body iron overload, or haemochromatosis // 2557959
FIELD: medicine.SUBSTANCE: method involves chelation of ferric (III) ions both in vivo, and in vitro with using 2-ethyl-6-methyl-3-hydroxypyridine succinate (Mexidol) to produce a stable stained complex having a high molecular weight and a complex (organic-inorganic) composition not identified among the known compounds.EFFECT: high effectiveness of the chelation process and low toxicity of Mexidol that makes it promising for biomedical application.4 dwg, 3 tbl, 3 ex

5(6)-nitro-1-(thietanyl-3)-2-ethoxybenzimidazole, inhibiting peroxidation of lipids // 2555832
FIELD: chemistry.SUBSTANCE: invention relates to field of organic chemistry, namely to novel compound - 5(6)-nitro-1-(thietanyl-3)-2-ethoxybenzimidazole, inhibiting peroxidation of lipids.EFFECT: novel compound, possessing useful biological properties, has been obtained.2 cl, 1 dwg, 2 ex

edication for treatment of cardiovascular diseases // 2555335
FIELD: medicine.SUBSTANCE: invention represents a mixture of two structural isomers: 2,6-di(1,7,7-trimethylbicyclo[2.2.1]hept-2-yl)-4-methylphenol and its diastereomers, and 2-(1,7,7-trimethylbicyclo[2.2.1]hept-2-yl)-6-(2,2,1-trimethylbicyclo[2.2.1]hept-5-yl)-4-methylphenol, and their diastereomers with the ratio of the first and second structural isomer isomers from 60:40 wt % to 95:5 wt %.EFFECT: extension of the arsenal of means, possessing simultaneously haemorheological, anti-aggregate, anti-thrombogenic, retinoprotecting, endothelium-protecting, neuroprotecting, anti-arrhythmia and anti-ischemic activity, enhancing the cerebral blood flow.4 dwg, 20 tbl, 6 ex

Agent for correcting pulmonary tissue disorders under cytostatic exposure // 2554776
FIELD: medicine.SUBSTANCE: what is presented is using Histochrom (same as echinochrome A or pentahydroxyethyl naphthoquinone) as an agent able to prevent pulmonary fibrosis developed under cytostatic agents. The invention can be used for the pharmacological prevention and correction of the pulmonary tissue disorders caused by administering the cytostatic agents.EFFECT: preventing hypertrophy of interalveolar connective tissue in the lungs associated with administering bleomycin.4 dwg, 1 tbl

Pletnev's drops possessing antiviral and immunomodulatory effects // 2553308
FIELD: medicine.SUBSTANCE: drops possessing antiviral and immunomodulatory effects characterised by the fact that they represent a 95% ethanol infusion of wild strawberry leaves and fruit specified in: red raspberry fruit, mountain ash fruit, bilberry fruit, blood-red hawthorn fruit, cinnamon rose fruit; 15-25 mg of the substance in 1 ml of the infusion.EFFECT: drops possess pronounced antiviral and immunomodulatory effects.15 tbl, 5 ex

ethod for preventing and treating acute radiation disease experimentally // 2551619
FIELD: medicine.SUBSTANCE: melanin having water-solubility of at least 80% and an paramagnetic centre concentration of at least 8·1017 spin/g is administered orally into the animals having been exposed to the radiation in a dose high enough to cause a spinal radiation injury; melanin is administered after dissolved in distilled water in the effective concentration. Melanin water is used as drinking water for the mice having been exposed to single and fractionated acute radiation, which is able to cause acute radiation disease. Melanin water is taken from the 1st to 30th day following the single radiation, or from the 1st day of the fractionated radiation to the 30th day on completion of the radiation.EFFECT: higher survival rate, faster recovered haemopoiesis, body weight and orientation and motion activity.7 tbl, 5 ex
Nadh composition having antioxidant properties // 2545920
FIELD: chemistry.SUBSTANCE: invention provides a composition having antioxidant properties in the form of a tablet, comprising an active agent based on nicotinamide adenine dinucleotide in reduced form (NADH) and inert filling agents, characterised by that the active ingredient is a complex which is a mixture of 10 wt % NADH with 63 wt % vegetable fats, 17 wt % beeswax and 10 wt % chlorophyll, and the inert filling agents are in the form of microcrystalline cellulose, Macrogol 6000, intense sweetener and a food flavourant.EFFECT: invention provides a new tablet form of NADH.1 ex

Pharmaceutical composition with anti-ischemic and antioxidant activity and method for preparing it // 2545833
FIELD: medicine.SUBSTANCE: invention refers to a pharmaceutical composition with anti-ischemic and antioxidant activity in the form of tablets or capsules, and a method for preparing it. The composition contains 4-((3-oxo-3-ethoxypropanoyl)amino)benzoic acid in an amount of 40 to 80 wt %, an amino-containing compound and pharmaceutically acceptable excipients. The amino-containing compound is specified in a group of trometamol, methyl glucamine and L-lysine; 1 mole of 4-((3-oxo-3-ethoxypropanoyl)amino)benzoic acid is accounted for 0.05 to 0.25 mole of the above amino-containing compound. The composition also contains lactose, microcrystalline cellulose, calcium stearate and other pharmaceutically acceptable excipients. According to the method for preparing the composition, taking 4-((3-oxo-3-ethoxypropanoyl)amino)benzoic acid and amino-containing compound in molar ratio 1:0.05 to 1:0.25, pre-mixing, moisturising with a aqueous or alcohol solution of a binding agent, adding pharmaceutically acceptable excipients in such an amount to provide the content of 4-((3-oxo-3-ethoxypropanoyl)amino)benzoic acid from 40 to 80 wt %, granulating the mixture, drying and producing tablets or capsules according to the known technique.EFFECT: implementing the above application.6 cl, 7 tbl, 4 ex
 
2550823.
Up!